Chronic lymphocytic leukemia

Surveillance, Epidemiology, and End Results (SEER) Program data (2000-2022) report the following relative survival rates (all stages) by time since diagnosis:[77]National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Explorer: all cancer sites combined- recent trends in SEER age-adjusted incidence rates, 2000-2023. 2026 [internet publication]. https://seer.cancer.gov/statistics-network/explorer/application.html

• 93.0% (2-year survival)

• 86.2% (5-year survival)

• 74.4% (10-year survival)

Targeted therapies, particularly Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib), B-cell lymphoma-2 protein (BCL2) inhibitors (e.g., venetoclax), and phosphoinositide 3-kinase (PI3K) inhibitors (e.g., duvelisib, idelalisib), are particularly useful in patients with a poor prognosis (del(17p) or TP53 mutation; relapsed/refractory disease).[58]Eichhorst B, Ghia P, Niemann CU, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024 Sep;35(9):762-8. https://www.annalsofoncology.org/article/S0923-7534(24)00747-6/fulltext http://www.ncbi.nlm.nih.gov/pubmed/38969011?tool=bestpractice.com ​​ Survival among patients with a poor prognosis may now exceed 8 years.[78]Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020 Jul 30;383(5):460-73. http://www.ncbi.nlm.nih.gov/pubmed/32726532?tool=bestpractice.com ​

Prognostic outcomes are likely to improve with increasing availability of targeted therapies.